๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Mitomycin C and menadione for the treatment of lung cancer: A phase II trial

Book ID
123099013
Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
137 KB
Volume
14
Category
Article
ISSN
0169-5002

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II trial of irinotecan, cisplatin
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer
โœ Dean A. Fennell; Jeremy P.C. Steele; Jonathan Shamash; Sarah E. Slater; Michael ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 87 KB ๐Ÿ‘ 1 views

## Abstract There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m^2^ Days 1 and 15 q28), cisplatin (40 mg/m^2^ Days 1 and 15 q28) and mitomycin (6 mg/m^2^ d1 q28) administered to a maximum

Mitomycin C, vinblastine, and carboplati
Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer: A phase II trial
โœ Adriano Paccagnella; Adolfo Favaretto; Francesco Oniga; Giuliana Festi; Stefano ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 702 KB

## BACKGROUND. The mitomycin C, vinblastine, and cisplatin (MVP) combination is one of the most frequently used in the palliative setting, but it produces considerable toxicity. Carboplatin and cisplatin have different patterns of toxicity. The goal of this study was to evaluate a combination simi